Cutting Out the Knots in Surgery

The needle-and-thread suturing process surgeons use to create anastomoses has been a staple in the OR, largely unchallenged for nearly a century. New developments in minimally invasive and endoscopic surgery, particularly in coronary bypass procedures, have created the need for a tissue-closure technique that can produce high-quality anastomoses in small spaces with limited visualization. As a result, anastomotic device technology, a long dormant area of product development, has become a hot subject at clinical meetings, and numerous companies, from major device firms to start-ups, are exploring a range of different approaches. Coalescent Surgical, a start-up, is one of the first to market in this area, with an anastomotic device that uses an approach different than its competitors--a proprietary self-closing clip that replaces traditional sutures. Coalescent's challenge: to gain acceptance from surgeons, who are notoriously slow adopters of new technology. The company is betting that the advantages of its device, combined with being first to market, will enable it to survive what appears will be a stampede of competitors, including major players that have superior resources and existing relationships with surgeons.

by Stephen Levin

From the mid-16th century, when the father of modern surgery, French military barber-surgeon Ambroise Pare, introduced the idea of stitching...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business Strategy

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By 

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

AI In Drug Discovery: The Patent Implications

 
• By 

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By 

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By 

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By 

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.